Literature DB >> 22914586

Negative depletion of CD3(+) and TcRαβ(+) T cells.

Rupert Handgretinger1.   

Abstract

PURPOSE OF REVIEW: In contrast to CD34(+) positive selection, negative depletion strategies retain large numbers of effector cells in allogeneic peripheral stem cell grafts, such as natural killer (NK) and other cells. This review summarizes the clinical experience obtained using negative depletion approaches of CD3(+) and T-cell receptor (TcR)αβ(+) T lymphocytes. RECENT
FINDINGS: Attempts to improve immune reconstitution and to better exploit the graft-versus-malignancy effect after transplantation of T-cell-depleted grafts through the preservation of immune effector cells led to the development of CD3-, CD3/CD19- and more recently TcRαβ/CD19-negative depletion strategies of mobilized peripheral stem cell grafts. A faster immune reconstitution has been observed in patients with negatively depleted grafts after haploidentical transplantation, although no prospective randomized trials have been reported to date. In a randomized study of matched sibling and matched unrelated transplantation, CD3/CD19-depleted peripheral stem cell grafts led to a faster recovery of NK cells compared with the CD34(+)-positive selection group.
SUMMARY: New technologies allow the large-scale graft engineering of peripheral stem cells for clinical use in matched and mismatched stem cell transplantation. Further clinical trials are necessary to decide which of these methods is associated with a faster immune reconstitution and a better outcome after transplantation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22914586     DOI: 10.1097/MOH.0b013e3283582340

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  25 in total

1.  Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis.

Authors:  D Teschner; E Distler; D Wehler; M Frey; D Marandiuc; K Langeveld; M Theobald; S Thomas; W Herr
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

Review 2.  How do I perform hematopoietic progenitor cell selection?

Authors:  Scott T Avecilla; Cheryl Goss; Sharon Bleau; Jo-Ann Tonon; Richard C Meagher
Journal:  Transfusion       Date:  2016-02-25       Impact factor: 3.157

Review 3.  Acute graft-versus-host disease: a bench-to-bedside update.

Authors:  Shernan G Holtan; Marcelo Pasquini; Daniel J Weisdorf
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

4.  Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRαβ+/CD19+-depleted grafts.

Authors:  Javid Gaziev; Antonella Isgrò; Pietro Sodani; Katia Paciaroni; Gioia De Angelis; Marco Marziali; Michela Ribersani; Cecilia Alfieri; Alessandro Lanti; Tiziana Galluccio; Gaspare Adorno; Marco Andreani
Journal:  Blood Adv       Date:  2018-02-13

5.  Aptamers as Reversible Sorting Ligands for Preparation of Cells in Their Native State.

Authors:  Bethany Powell Gray; Martin D Requena; Michael D Nichols; Bruce A Sullenger
Journal:  Cell Chem Biol       Date:  2019-12-23       Impact factor: 8.116

6.  Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts.

Authors:  M A Diaz; A Pérez-Martínez; B Herrero; N Deltoro; I Martinez; M Ramirez; L Abad; J Sevilla; E Merino; J Ruiz; J L Vicario; M Gonzalez-Vicent
Journal:  Bone Marrow Transplant       Date:  2016-04-18       Impact factor: 5.483

7.  Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study.

Authors:  J Foell; B Pfirstinger; K Rehe; D Wolff; E Holler; S Corbacioglu
Journal:  Bone Marrow Transplant       Date:  2017-04-24       Impact factor: 5.483

Review 8.  Allo-reactive T cells for the treatment of hematological malignancies.

Authors:  J H F Falkenburg; I Jedema
Journal:  Mol Oncol       Date:  2015-10-24       Impact factor: 6.603

9.  NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).

Authors:  Moniek A de Witte; Jürgen Kuball; Jeffrey S Miller
Journal:  Curr Stem Cell Rep       Date:  2017-10-16

Review 10.  Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust.

Authors:  Moniek de Witte; Laura G M Daenen; Lotte van der Wagen; Anna van Rhenen; Reiner Raymakers; Kasper Westinga; Jürgen Kuball
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.